Replies to post #250533 on Biotech Values

[sks144]

So do you think it’s going to fail based on the 1L population? I do think the drug has shown a tell tale IO sign in the long tail on the KP curves and the fact those receiving subsequent SACT seem to be doing much better in real world follow up

[sks144]

Yes the clinical trail site should have been updated as this change was made long ago.

I really hope the OS benefit in aggregate they saw in the P2 wasn’t a fluke and they can recreate in the P3

They have set a .61 bar for HR at 80% of events for the interim.

Let’s see